Aberdeen Group’s 10x Genomics TXG Stock Holding History

Aberdeen Group’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,394	Closed	-$203K	–	1071
2021 Q3	$203K	Sell	1,394 -42	-3%	-$7.21K	﹤0.01%	1034
2021 Q2	$281K	Sell	1,436 -1,019	-42%	-$184K	﹤0.01%	985
2021 Q1	$444K	Buy	2,455 +263	+12%	+$45.4K	﹤0.01%	921
2020 Q4	$310K	Sell	2,192 -1,633	-43%	-$237K	﹤0.01%	921
2020 Q3	$477K	Buy	+3,825	New	+$402K	﹤0.01%	851
2020 Q2	–	Sell	-3,958	Closed	-$247K	–	941
2020 Q1	$247K	Buy	+3,958	New	+$309K	﹤0.01%	886

Other funds holding TXG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Aberdeen Group's TXG Position: Q4 2021 in Review

Aberdeen Group sold out of 10x Genomics (TXG) in Q4 2021, closing a stake of 1,394 shares — an estimated $203K sold.

Aberdeen Group first reported a position in TXG in Q1 2020 and held it in 6 quarters. The position peaked at $477K in Q3 2020. 365 funds tracked by Wall St. Rank hold TXG as of Q4 2021.

Aberdeen Group reported no remaining 10x Genomics position as of Q4 2021 after selling out during the quarter.
Aberdeen Group sold 1,394 10x Genomics shares in Q4 2021, an estimated $203K.
Aberdeen Group first reported a position in 10x Genomics in Q1 2020 and held it in 6 quarters.
Aberdeen Group's 10x Genomics position peaked at $477K in Q3 2020.
365 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2021.

Based on Aberdeen Group's 13F filing for Q4 2021, filed 8 Feb 2022.